Probiotics as a Treatment for “Metabolic Depression”? A Rationale for Future Studies

Gawlik-Kotelnicka, Oliwia; Strzelecki, Dominik

doi:10.3390/ph14040384

Cited by 15 publications

(16 citation statements)

References 179 publications

(199 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The optimal probiotics strains and dosages, intervention length and outcome measures were selected based on our previous investigation [ 47 ].…”

Section: Methodsmentioning

confidence: 99%

“…For example, there is limited but promising evidence with regard to the effectiveness of probiotics regarding the risk of depressiveness or anxiety in the perinatal period [ 44 , 45 ], and probiotics may have a favorable effect on overweight-induced cognitive impairment and anxiety [ 46 ]. More specifically, little is known whether probiotic mixtures have favorable effects on psychometric, metabolic and inflammation measures in a population with depression, with or without MetS as a comorbidity [ 47 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

PRO-DEMET Randomized Controlled Trial on Probiotics in Depression—Pilot Study Results

et al. 2023

View full text Add to dashboard Cite

There is a pressing need to identify new treatment options for depression and its comorbidities. Depression often coexists with metabolic complications, and the two may share a pathophysiological overlap, including inflammation and microbiota changes. Microbiota interventions (e.g., probiotics) may represent a safe and easy-to-use treatment option as an adjunctive therapy in patients only partially responsive to pharmacologic treatment. (1) Objective: The paper presents the results of a feasibility and pilot study. The study is an internal part of a randomized controlled trail (RCT) of the effect of probiotic supplementation on psychometric, anthropometric, metabolic, and inflammatory parameters in adult patients with depressive disorders depending on the presence of metabolic syndrome. (2) Methods: The trial has a four-arm, parallel-group, prospective, randomized, double-blind, controlled design. Sixty participants received a probiotic preparation containing Lactobacillus helveticus Rosell®-52 and Bifidobacterium longum Rosell®-175 over 60 days. The feasibility of the study design was assessed, as well as the rates of recruitment, eligibility, consent, and study completion. The following were assessed: depressive, anxiety and stress symptoms, quality of life, blood pressure, body mass index and waist circumference, complete blood count with differential, serum levels of C-reactive protein, high-density lipoprotein cholesterol, triglycerides, fasting glucose, some secondary markers of inflammation and metabolic health, as well as noninvasive biomarkers of liver fibrosis (APRI and FIB-4). (3) Results: The study was found to be generally feasible. The eligibility rate was 52% of recruited participants with 80% completing the study protocol. No differences in sociodemographic or anthropometric factors or basic laboratory findings were found between the placebo and probiotic group at the start of the intervention period. Importantly, the proportion of recruited participants fulfilling the criteria of metabolic syndrome was too low. (4) Conclusions: Whilst the whole study protocol was feasible, some different timepoint procedures require modification. The major weakness of the recruitment methods was that the percentage of metabolic arms participants was insufficient. Overall, the full RCT design on probiotics in depression with vs. without metabolic syndrome was shown to be feasible with little modification.

show abstract

“…The optimal probiotics strains and dosages, intervention length and outcome measures were selected based on our previous investigation [ 47 ].…”

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

PRO-DEMET Randomized Controlled Trial on Probiotics in Depression—Pilot Study Results

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Moreover, evidence reports probiotics have denoted effectiveness in reducing depressive symptoms when combined with antidepressants and ameliorating the coexisting metabolic disorders, but there are no standardized recommendations for MDD [210]. Popularly known, Lactobacillus and Bifidobacterium have been the most extensively used genera for the restraint of undesired bacteria (i.e., overgrowth of Escherichia coli or the opportunistic infection of Citrobacter rodentium) and the strengthening of intestinal epithelia in gastrointestinal disorders.…”

Section: Emulation Of Microbial Metabolism 421 Adjuvant Therapy Suppl...mentioning

confidence: 99%

Gut Microbiota Metabolites in Major Depressive Disorder—Deep Insights into Their Pathophysiological Role and Potential Translational Applications

et al. 2022

View full text Add to dashboard Cite

The gut microbiota is a complex and dynamic ecosystem essential for the proper functioning of the organism, affecting the health and disease status of the individuals. There is continuous and bidirectional communication between gut microbiota and the host, conforming to a unique entity known as “holobiont”. Among these crosstalk mechanisms, the gut microbiota synthesizes a broad spectrum of bioactive compounds or metabolites which exert pleiotropic effects on the human organism. Many of these microbial metabolites can cross the blood–brain barrier (BBB) or have significant effects on the brain, playing a key role in the so-called microbiota-gut-brain axis. An altered Microbiota-Gut-Brain (MGB) axis is a major characteristic of many neuropsychiatric disorders, including major depressive disorder (MDD). Significative differences between gut eubiosis and dysbiosis in mental disorders like MDD with their different metabolite composition and concentrations are being discussed. In the present review, the main microbial metabolites (short-chain fatty acids -SCFAs-, bile acids, amino acids, tryptophan -trp- derivatives, and more), their signaling pathways and functions will be summarized to explain part of MDD pathophysiology. Conclusions from promising translational approaches related to microbial metabolome will be addressed in more depth to discuss their possible clinical value in the management of MDD patients.

show abstract

“…In the tangled mess of the multiple factors involved in MDD, gut dysbiosis and intestinal complaints are frequent. Evidence alleges that probiotics are effective in ameliorating depressive symptoms when administered with antidepressants, not only for the gut–brain axis but also for the metabolic disturbances of comorbidities that are particularly frequent in MDD (metabolic syndrome) [ 189 ]. Nevertheless, standardized methods to measure probiotics efficacy in clinical trials remain unclear.…”

Section: Nutraceuticals In Mddmentioning

confidence: 99%

Exploring the Role of Nutraceuticals in Major Depressive Disorder (MDD): Rationale, State of the Art and Future Prospects

et al. 2021

View full text Add to dashboard Cite

Major depressive disorder (MDD) is a complex and common disorder, with many factors involved in its onset and development. The clinical management of this condition is frequently based on the use of some pharmacological antidepressant agents, together with psychotherapy and other alternatives in most severe cases. However, an important percentage of depressed patients fail to respond to the use of conventional therapies. This has created the urgency of finding novel approaches to help in the clinical management of those individuals. Nutraceuticals are natural compounds contained in food with proven benefits either in health promotion or disease prevention and therapy. A growing interest and economical sources are being placed in the development and understanding of multiple nutraceutical products. Here, we summarize some of the most relevant nutraceutical agents evaluated in preclinical and clinical models of depression. In addition, we will also explore less frequent but interest nutraceutical products which are starting to be tested, also evaluating future roads to cover in order to maximize the benefits of nutraceuticals in MDD.

show abstract

Probiotics as a Treatment for “Metabolic Depression”? A Rationale for Future Studies

Cited by 15 publications

References 179 publications

PRO-DEMET Randomized Controlled Trial on Probiotics in Depression—Pilot Study Results

PRO-DEMET Randomized Controlled Trial on Probiotics in Depression—Pilot Study Results

Gut Microbiota Metabolites in Major Depressive Disorder—Deep Insights into Their Pathophysiological Role and Potential Translational Applications

Exploring the Role of Nutraceuticals in Major Depressive Disorder (MDD): Rationale, State of the Art and Future Prospects

Contact Info

Product

Resources

About